| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Cell membranes; intracellular delivery targets. MPG peptides, Pβ is a primary amphiphilic peptide consisting of three domains. Its amphipathic nature allows it to interact with cell membranes and penetrate into cells. The peptide does not have a specific pharmacological target but functions as a cell-penetrating peptide (CPP) that facilitates the intracellular delivery of drugs, therapeutic nucleic acids, and nanoparticles. Its mechanism of action involves membrane interaction and translocation, enabling cargo delivery to intracellular targets.
|
|---|---|
| ln Vitro |
MPG peptides, Pβ is a cell-penetrating peptide that enhances the intracellular delivery of various biomolecules. The peptide’s amphipathic nature enables efficient membrane penetration and cargo delivery. It has been used in the delivery of HIV-1 multi-epitope DNA and peptide constructs. In vitro studies have demonstrated its ability to improve the intracellular uptake and bioavailability of specific drugs or gene therapies. The peptide itself does not exhibit pharmacological activity but serves as a delivery vehicle.
|
| ln Vivo |
In vivo studies of MPG peptides, Pβ have shown promising results in treating diseases such as cancer, genetic disorders, and viral infections by improving the intracellular uptake and bioavailability of therapeutic agents. The peptide’s ability to deliver nucleic acids and drugs to target cells makes it a valuable tool for gene therapy and drug delivery applications. Further in vivo studies are needed to fully characterize its efficacy and safety in various disease models.
|
| Enzyme Assay |
Non-cell-based assays for MPG peptides, Pβ include biophysical characterization of its amphipathic properties and membrane interaction. Standard analytical methods including HPLC, mass spectrometry, and circular dichroism spectroscopy are used for compound characterization and purity assessment. The peptide’s ability to form complexes with nucleic acids or drugs can be assessed using gel retardation assays or fluorescence-based methods.
|
| Cell Assay |
Cell-based assays for MPG peptides, Pβ use various cell lines to assess its cell-penetrating and cargo delivery efficiency. Cells are treated with fluorescently labeled peptide or peptide-cargo complexes, and intracellular uptake is assessed by fluorescence microscopy or flow cytometry. The peptide’s ability to deliver therapeutic nucleic acids is assessed by measuring target gene expression or functional effects. Cytotoxicity is assessed using standard cell viability assays.
|
| Animal Protocol |
In vivo studies of MPG peptides, Pβ are conducted in animal models of cancer, genetic disorders, and viral infections. The peptide is administered as a complex with therapeutic cargo via various routes (intravenous, intratumoral, or local injection). Therapeutic efficacy is assessed by measuring disease progression, target gene expression, or biomarker levels. Biodistribution and pharmacokinetic parameters are determined from tissue and blood samples.
|
| ADME/Pharmacokinetics |
MPG peptides, Pβ has a molecular formula of C₁₂₉H₂₀₈N₃₆O₃₂S and a molecular weight of 2807.32 g/mol. The peptide sequence is H-Gly-Ala-Leu-Phe-Leu-Gly-Phe-Leu-Gly-Ala-Ala-Gly-Ser-Thr-Met-Gly-Ala-Trp-Ser-Gln-Pro-Lys-Lys-Lys-Arg-Lys-Val-OH. It is soluble in water (≥50 mg/mL). Storage: -20°C, protected from light, dry, and sealed. Aliquot to avoid multiple freeze/thaw cycles.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for MPG peptides, Pβ are limited. As a cell-penetrating peptide, it may have membrane-active properties that could cause cytotoxicity at high concentrations. The peptide is intended for research use only and is not for human therapeutic applications. Standard laboratory safety practices should be followed when handling this compound.
|
| References |
[1]. Davoodi S, et al. Design and in vitro delivery of HIV-1 multi-epitope DNA and peptide constructs using novel cell-penetrating peptides. Biotechnol Lett. 2019 Nov;41(11):1283-1298.
[2]. Zhang XX, et al. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release. 2012 Apr 10;159(1):2-13. |
| Additional Infomation |
MPG peptides, Pβ is a primary amphiphilic cell-penetrating peptide consisting of three domains. It has been extensively studied for its potential in enhancing the intracellular delivery of drugs, therapeutic nucleic acids, and nanoparticles. The peptide’s amphipathic nature allows it to interact with and penetrate cell membranes. It has shown promising results in treating diseases such as cancer, genetic disorders, and viral infections. It is intended for research use only.
|
| Molecular Formula |
C129H208N36O32S
|
|---|---|
| Molecular Weight |
2807.31884765625
|
| Exact Mass |
2806.55
|
| CAS # |
791642-10-9
|
| PubChem CID |
170900415
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-6.5
|
| Hydrogen Bond Donor Count |
39
|
| Hydrogen Bond Acceptor Count |
39
|
| Rotatable Bond Count |
95
|
| Heavy Atom Count |
198
|
| Complexity |
6140
|
| Defined Atom Stereocenter Count |
23
|
| SMILES |
C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CN)O
|
| InChi Key |
QROMJFGAVBMXMZ-YVNWPWPGSA-N
|
| InChi Code |
InChI=1S/C129H208N36O32S/c1-69(2)55-90(159-120(188)93(58-78-33-17-15-18-34-78)148-103(173)66-143-113(181)91(56-70(3)4)160-121(189)94(59-79-35-19-16-20-36-79)161-119(187)92(57-71(5)6)157-109(177)75(11)144-100(170)61-134)112(180)142-64-102(172)145-74(10)108(176)147-73(9)107(175)140-65-104(174)149-96(67-166)124(192)164-106(77(13)168)126(194)155-88(47-54-198-14)111(179)141-63-101(171)146-76(12)110(178)158-95(60-80-62-139-82-38-22-21-37-81(80)82)122(190)162-97(68-167)123(191)156-89(45-46-99(135)169)127(195)165-53-32-44-98(165)125(193)154-85(41-25-29-50-132)116(184)151-83(39-23-27-48-130)114(182)150-84(40-24-28-49-131)115(183)153-87(43-31-52-138-129(136)137)117(185)152-86(42-26-30-51-133)118(186)163-105(72(7)8)128(196)197/h15-22,33-38,62,69-77,83-98,105-106,139,166-168H,23-32,39-61,63-68,130-134H2,1-14H3,(H2,135,169)(H,140,175)(H,141,179)(H,142,180)(H,143,181)(H,144,170)(H,145,172)(H,146,171)(H,147,176)(H,148,173)(H,149,174)(H,150,182)(H,151,184)(H,152,185)(H,153,183)(H,154,193)(H,155,194)(H,156,191)(H,157,177)(H,158,178)(H,159,188)(H,160,189)(H,161,187)(H,162,190)(H,163,186)(H,164,192)(H,196,197)(H4,136,137,138)/t73-,74-,75-,76-,77+,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,105-,106-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-aminoacetyl)amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]propanoyl]amino]propanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 50 mg/mL (17.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3562 mL | 1.7811 mL | 3.5621 mL | |
| 5 mM | 0.0712 mL | 0.3562 mL | 0.7124 mL | |
| 10 mM | 0.0356 mL | 0.1781 mL | 0.3562 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
